Nuvation Bio Inc. Class A Common Stock (NUVB)

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment o…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

305

Website

www.nuvationbio.com/

Fundamentals

1-day range

$7.02$7.58

Market cap

$2.13B

P/E (trailing)

—

P/E (forward)

-484.00

EPS (trailing)

$-0.44

Dividend yield

—

Beta

1.60

Avg. volume

6.73M

Forecasts

9 analyst ratings

Nuvation Bio Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• NUVB

  Nuvation Bio Inc. Class A Common Stock

  $6.67

  ▼ 4.65%
  Market cap $2.13BP/E —
  $2.87$9.75
• AUPH

  Aurinia Pharmaceuticals Inc Ordinary Shares

  $16.3

  ▼ 1.09%
  Market cap $2.10BP/E 6.39
  $10.34$19.25
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.17BP/E —
  $7.48$18.57
• SLS

  SELLAS Life Sciences Group Inc. Common Stock

  $13.17

  ▼ 13.45%
  Market cap $2.18BP/E —
  $1.39$15.88
• HCM

  HUTCHMED (China) Limited American Depositary Shares

  $12.4

  ▼ 0.12%
  Market cap $2.06BP/E 4.74
  $15.57$28.8
• STOK

  Stoke Therapeutics Inc. Common Stock

  $31.61

  ▼ 3.01%
  Market cap $2.06BP/E —
  $18.8$40.22
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $2.22BP/E —
  $15.86$50.81

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cantor Fitzgerald Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation
  Fintel · 8/21/2026
• This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
  Benzinga · 8/21/2026
• This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
  Benzinga · 8/21/2026
• This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
  Benzinga · 8/21/2026
• Cantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating
  Benzinga · 8/21/2026
• Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1
  Benzinga · 8/20/2026
• JP Morgan Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation
  Fintel · 8/19/2026
• JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
  Benzinga · 8/18/2026

• Philippe Sauvage · July 15, 2026 · Option Exercise

  1 @ $1.97
• Philippe Sauvage · July 15, 2026 · Option Exercise

  40.0K @ $2.17
• Kerry Wentworth · June 23, 2026 · Option Exercise

  63.0K @ $2.93
• Kerry Wentworth · June 23, 2026 · Sale

  63.0K @ $6.02
• Philippe Sauvage · June 23, 2026 · Option Exercise

  47.7K @ $2.17
• Philippe Sauvage · June 23, 2026 · Sale

  47.7K @ $6.01
• Stacy Markel · June 23, 2026 · Option Exercise

  34.6K @ $1.74
• Stacy Markel · June 23, 2026 · Option Exercise

  90.4K @ $1.87
• Stacy Markel · June 23, 2026 · Sale

  125.0K @ $6.03
• Robert Mashal · June 9, 2026 · Buy

  25.0K @ $4.73
• Robert Mashal · May 21, 2026 · Grant

  123.4K
• Robert B. Bazemore · May 21, 2026 · Grant

  123.4K
• Cui Xiangmin · May 21, 2026 · Grant

  123.4K
• VERNON W ANTHONY · May 21, 2026 · Grant

  123.4K
• BLICKENSTAFF KIM D · May 21, 2026 · Grant

  123.4K

Institutional Ownership

March 31, 2026

Total shares held

217.14M

Total value held

$894.03M

Institutional holders

224